IMDX vs WST · rev $271.0K vs P/E 35, rev $1.72B
Insight Molecular Diagnostics Inc. (IMDX) versus West Pharmaceutical Services Inc (WST) — a side-by-side from cached financials, not a winner call.
Insight Molecular Diagnostics Inc. (IMDX) is a diagnostics & research company listed on US.
West Pharmaceutical Services Inc (WST) is a medical instruments & supplies company listed on US.
Latest reported IMDX revenue for 2026-06-30 was $271.0K. Net income was -$15.6M. IMDX currently screens at market cap $0.
Latest reported WST revenue for 2026-06-30 was $1.72B. Net income was $292.8M. WST currently screens at market cap $15.97B and trailing P/E 34.8.
IMDX currently screens at market cap $0. WST currently screens at market cap $15.97B and trailing P/E 34.8.
Not investment advice. Open the IMDX and WST stock pages for the full models.
Not investment advice.